川普吹捧的抗病毒药被此国叫停：四分之一测试患者心脏出问题！

Trial of high doses of malaria drug to treat coronavirus in Brazil stopped early after A QUARTER of patients developed heart problems
巴西治疗冠状病毒的大剂量疟疾药物的试验在四分之一的患者出现心脏问题后提前停止

来源：每日邮报 翻译：世界播APP

Scientists in Brazil have stopped part of a study of a malaria drug touted as a possible coronavirus treatment after heart rhythm problems developed in one-quarter of people given the higher of two doses being tested.

巴西科学家停止了一项关于一种疟疾药物的部分研究，该药物被吹捧为一种可能的冠状病毒治疗方法，此前四分之一的人出现了心律问题，服用了两种测试剂量中较高的一种。

Chloroquine and a newer, similar drug called hydroxychloroquine, have been pushed by President Donald Trump after some early tests suggested the drugs might curb the virus from entering cells.

氯喹和一种名为羟基氯喹的较新的类似药物，在一些早期测试表明这些药物可能会抑制病毒进入细胞后，一直受到唐纳德·特朗普(Donald Trump)总统的推动。

But the drugs have long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death.

但长期以来，人们一直知道这些药物有潜在的严重副作用，包括以一种可能导致猝死的方式改变心跳。

The Brazilian study, in the Amazonian city of Manaus, had planned to enroll 440 severely ill COVID-19 patients to test two doses of chloroquine, but researchers reported results after only 81 had been treated.

巴西的这项研究在亚马逊城市马瑙斯进行，原计划招募440名重病COVID-19患者来测试两剂氯喹，但研究人员只在81名患者接受治疗后报告了结果。

One-fourth of those assigned to get 600 milligrams twice a day for 10 days developed heart rhythm problems, and trends suggested more deaths were occurring in that group, so scientists stopped that part of the study.

那些被分配每天两次服用600毫克的人中，有四分之一在10天内出现了心律问题，趋势表明这组人中发生了更多的死亡，所以科学家停止了这部分研究。

The other group was given 450 milligrams twice a day on the first day then once a day for four more days.

另一组在第一天每天服用450毫克，两次，然后每天服用一次，持续四天。

That is closer to what is being tried in some other studies including some in the US.

这与其他一些研究(包括美国的一些研究)的实验结果更接近。

It's too soon to know whether that will prove safe or effective; the Brazil study had no comparison group that was getting no treatment.

现在就知道这是否安全或有效还为时过早；巴西的研究没有没有接受治疗的对照组。

Only one participant in the Brazil study had no signs of the virus in throat swabs after treatment, researchers noted.

研究人员指出，在巴西的研究中，只有一名参与者在治疗后的咽拭子中没有发现病毒的迹象。

The results from the Brazil study were posted on a research website and have not yet been reviewed by other scientists.

巴西的研究结果发布在一个研究网站上，还没有经过其他科学家的审查。

Complicating matters is that all patients in the study also received two antibiotics, ceftriaxone and azithromycin.

更复杂的是，研究中的所有患者都接受了两种抗生素，头孢曲松和阿奇霉素。

The latter also can have side effects on the heart.Trump has touted the hydroxychloroquine-azithromycin combination.

后者也会对心脏产生副作用。特朗普吹捧羟基氯喹和阿奇霉素的组合。

Brazil's President Jair Bolsonaro has also repeatedly hailed the benefits of chloroquine and azithromycin without evidence.

巴西总统贾尔·博尔索纳罗(Jair Bolsonaro)也多次在没有证据的情况下称赞氯喹和阿奇霉素的好处。

He said at one point he heard reports of 100 percent effectiveness when administered in the correct dosages, zeroed tariffs for import of the drugs, and late last month announced military labs were ramping up their chloroquine production.

他说，他一度听到报告称，在正确的剂量下服用是100%有效的，对药物的进口关税为零，并于上月底宣布军事实验室正在增加氯喹的生产。

In reality, results of trials of hydroxychloroquine have been mixed.

实际上，羟基氯喹的试验结果好坏参半。

The drug is already being widely deployed in countries like South Korea and China, but data on its safety and efficacy are still being collected in those countries as well as in the US.

该药物已经在韩国和中国等国得到广泛应用，但有关其安全性和有效性的数据仍在这些国家以及美国收集。

As cases of coronavirus in the US continue to mount past 570,000, the search for an effective treatment is intensifying with tests of hydroxychloroquine and remdesivir across the US

随着美国冠状病毒病例继续增加到57万例以上，随着全美各地对羟基氯喹和瑞希韦的检测，寻找有效治疗方法的工作正在加紧进行。

However, a recent worldwide survey found that hydroxychloroquine was not only the potential treatment used most often by doctors internationally, but the one they thought most likely to be effective.

然而，最近的一项全球调查发现，羟基氯喹不仅是国际医生最常使用的潜在治疗方法，而且是他们认为最有可能有效的治疗方法。

Brazil's trial failure comes amid growing concerns that coronavirus itself may attack the heart.

巴西试验失败的同时，人们越来越担心冠状病毒本身可能会攻击心脏。

The first evidence that the virus may be dangerous to the heart came out of China, which, as the origin of coronavirus, has been the bellwether for the disease's patterns.

这种病毒可能对心脏构成危险的第一个证据来自中国，作为冠状病毒的发源地，中国一直是这种疾病模式的风向标。

Nearly 20 percent of 416 hospitalized coronavirus patients in one study conducted there showed signs of heart damage.

在那里进行的一项研究中，在416名住院的冠状病毒患者中，近20%显示出心脏损伤的迹象。

And more than half of the patients that had heart damage died while hospitalized for coronavirus.By comparison, just 4.5 percent of patients without heart damage died.

超过一半的心脏损伤患者在因冠状病毒住院期间死亡。相比之下，没有心脏损伤的患者中只有4.5%死亡。

This month, daily coronavirus in the US have surpassed 1,000 every day but one

本月，美国每天都有冠状病毒超过1000例，只有一例除外。

Unsurprisingly, rates of heart damage from coronavirus were much higher among people who already had heart disease before they were infected.

不足为奇的是，冠状病毒对心脏的损伤率在感染前就已经患有心脏病的人要高得多。

But worryingly, the patients with no prior health conditions were hit hardest by the heart damage they suffered while infected with coronavirus.

但令人担忧的是，之前没有健康状况的患者在感染冠状病毒时受到的心脏损伤打击最大。

This smaller group of patients was at greater risk of dying from heart-related complications of the disease.

这一较小的患者群体死于与心脏相关的疾病并发症的风险更大。

Still, as is the case with all facets of COVID-19, older people and those with underlying health conditions are hardest hit by its cardiac effects as well.

尽管如此，就像COVID-19的所有方面一样，老年人和那些有潜在健康状况的人也受到其心脏影响的最严重影响。

Doctors believe that inflammation triggered by coronavirus, the virus's potential ability to attack blood vessels and to infect the heart itself may trigger heart attacks or heart failure in COVID-19 patients.

医生们认为，冠状病毒引发的炎症，病毒攻击血管和感染心脏本身的潜在能力，可能会在COVID-19患者中引发心脏病发作或心力衰竭。

So the combination of the impact of coronavirus itself on the heart combined with hydroxychloroquine's potential to trigger heart arrhythmias could prove dangerous to patients.

因此，冠状病毒本身对心脏的影响与羟氯喹引发心律失常的潜力相结合，可能会证明对患者是危险的。

But it may be that at a lower dose - an NIH trial is giving patients two 400mg doses of the drug on the first day of treatment, followed by 200mg twice daily for the following eight days - the drug poses a lesser cardiac risk.

但可能是在较低的剂量下-NIH的一项试验在治疗的第一天给患者两剂400毫克的药物，然后在接下来的八天里每天两次服用200毫克-这种药物对心脏的风险较小。